Holen Sie sich die Stockscreener-App
35.63
1.79%
-0.65
Schlusskurs vom Vortag:
$36.28
Offen:
$36.13
24-Stunden-Volumen:
1.12M
Relative Volume:
1.34
Marktkapitalisierung:
$2.82B
Einnahmen:
$399.58M
Nettoeinkommen (Verlust:
$-54.04M
KGV:
-47.51
EPS:
-0.75
Netto-Cashflow:
$40.13M
1W Leistung:
-0.39%
1M Leistung:
-14.54%
6M Leistung:
+20.82%
1J Leistung:
-13.20%
1-Tages-Spanne:
$35.18
$36.45
1-Wochen-Bereich:
$35.18
$37.22
52-Wochen-Spanne:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
35.63 | 2.87B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
510.93 | 193.53B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.50 | 149.33B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
635.66 | 50.36B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
122.90 | 35.73B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
333.33 | 32.24B | 3.17B | 642.63M | 539.81M | 10.77 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Underweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Hold |
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Veracyte Inc (NASDAQ:VCYT): A Prime GARP Stock with Strong Growth and a Sound Balance Sheet - ChartMill
Jupiter Asset Management Ltd. Acquires New Stake in Veracyte, Inc. $VCYT - MarketBeat
Veracyte to Participate in Upcoming Investor Conferences - Business Wire
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - Finviz
Illinois Municipal Retirement Fund Takes Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (VCYT) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Assessing Veracyte (VCYT) Valuation After Recent Share Price Volatility - Yahoo Finance
What Veracyte (VCYT)'s UBS Rating Reaffirmation and 2026 Outlook Means For Shareholders - Yahoo Finance
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings - Bitget
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro - Finviz
Public Sector Pension Investment Board Invests $10.54 Million in Veracyte, Inc. $VCYT - MarketBeat
UBS reaffirmed buy rating on Veracyte (VCYT) after strong Q4 testing revenue - MSN
UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue - Insider Monkey
Why Veracyte Inc. (12V) stock signals breakout potential2025 Winners & Losers & Free Reliable Trade Execution Plans - mfd.ru
13 Best Innovative Stocks to Buy According to Wall Street Analysts - Insider Monkey
Is Veracyte Inc. stock gaining market shareGold Moves & Expert Curated Trade Setups - mfd.ru
Pharma News: What is the next catalyst for Veracyte IncJuly 2025 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
Veracyte (NASDAQ:VCYT) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Is Veracyte Inc. exposed to currency risks2025 Valuation Update & Daily Profit Maximizing Trade Tips - mfd.ru
56,756 Shares in Veracyte, Inc. $VCYT Bought by Thrivent Financial for Lutherans - MarketBeat
Is Veracyte Inc.’s ROIC above industry averageTrade Volume Report & Free Community Consensus Stock Picks - mfd.ru
Can Veracyte Inc. expand into new marketsJuly 2025 Selloffs & Real-Time Buy Signal Notifications - mfd.ru
Why Veracyte Inc. stock is considered a top pickJuly 2025 Final Week & Reliable Entry Point Trade Alerts - mfd.ru
Veracyte, Inc. $VCYT Stock Holdings Increased by Allianz Asset Management GmbH - MarketBeat
Sentiment Watch: What are the future prospects of Veracyte Inc2025 Trading Volume Trends & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is Veracyte (VCYT) Pricing Reflect Future Cash Flows After Multi Year Share Price Slide - Yahoo Finance
Federated Hermes Inc. Sells 52,039 Shares of Veracyte, Inc. $VCYT - MarketBeat
Principal Financial Group Inc. Boosts Stake in Veracyte, Inc. $VCYT - MarketBeat
How Veracyte Inc. stock responds to policy changesWeekly Risk Summary & AI Powered Buy/Sell Recommendations - mfd.ru
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $4.78 Million Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail
Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - BioSpace
Veracyte is Now Oversold (VCYT) - Nasdaq
Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance
Aug Fed Impact: Can Veracyte Inc generate free cash flowJuly 2025 Earnings & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Veracyte’s Growth Story Hit A Valuation Wall - Finimize
Growth Recap: What is the Moat Score of Data Storage Corporation2025 Market Outlook & AI Driven Price Predictions - baoquankhu1.vn
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Improved Revenues Required Before Veracyte, Inc. (NASDAQ:VCYT) Shares Find Their Feet - 富途牛牛
Targets Report: What makes Veracyte Inc. stock attractive today2025 Major Catalysts & AI Powered Trade Plan Recommendations - baoquankhu1.vn
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test - Nasdaq
Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now - Finviz
Reasons to Retain Avanos Medical Stock in Your Portfolio Now - Finviz
Can Veracyte Inc. ride the EV waveQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru
Earnings Miss: Can Veracyte Inc expand into new marketsEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
Veracyte, Inc. (VCYT) Stock Analysis: A Diagnostic Leader With 17.49% Potential Upside - DirectorsTalk Interviews
Why Veracyte (VCYT) is poised to beat earnings estimates again - MSN
CLPT Gets EU MDR Certification for ClearPoint Navigation Software - Finviz
Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating - MSN
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again - Prime Publishers, Inc.
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):